{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T02:52:13Z","timestamp":1793847133760,"version":"4.6.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":58,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"crossref","award":["313106\/2020-7"],"award-info":[{"award-number":["313106\/2020-7"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Triple-negative breast cancer (TNBC) is an aggressive and immunogenic breast cancer subtype frequently associated with BRCA1 alterations. Inflammation and innate immune sensing pathways, including inflammasomes, play complex and context-dependent roles in tumor progression and anti-tumor immunity. However, the prognostic significance of inflammasome components in TNBC remains poorly defined. We evaluated the protein expression of key inflammasome components including NLR family pyrin domain-containing 3 (NLRP3), PYD and CARD domain-containing protein (PYCARD), caspase-1 (CASP1), and interleukin-18 (IL-18) by immunohistochemistry in tumor samples from 88 TNBC patients stratified by BRCA1 status, including pathogenic germline mutations, promoter hypermethylation, and wild-type tumors. Survival analyses were performed using Kaplan\u2013Meier estimates and Cox proportional hazards models. Lower CASP1 expression was significantly associated with smaller tumor size (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.005), whereas lower NLRP3 expression was associated with axillary lymph node metastasis (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.003). No significant association was observed between inflammasome protein expression and BRCA1 mutation or promoter hypermethylation status. Importantly, low NLRP3 expression was independently associated with worse disease-free survival (DFS) (hazard ratio (HR)\u2009=\u20093.15, 95% confidence interval (CI)\u2009=\u20091.36 to 7.30,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.007) and overall survival (OS) (HR\u2009=\u20092.63, 95% CI\u2009=\u20091.19 to 5.79,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.01). These findings indicate that reduced NLRP3 expression is associated with unfavorable prognosis in TNBC. Although exploratory in nature, this study highlights the potential relevance of inflammasome components as prognostic biomarkers in this aggressive breast cancer subtype and warrants further validation in independent cohorts.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-43392-0","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T13:23:54Z","timestamp":1774099434000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Analysis of the NLRP3 inflammasome components expression in triple-negative breast cancer patients with and without BRCA1 mutations"],"prefix":"10.1038","volume":"16","author":[{"given":"Sara Socorro","family":"Faria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Costantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Di Gennaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladmir C. Cordeiro","family":"de Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor Piana","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano","family":"de P\u00e1dua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vin\u00edcius","family":"Duval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia Maria Chiquitelli","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly Grace","family":"Magalh\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,21]]},"reference":[{"key":"43392_CR1","doi-asserted-by":"publisher","first-page":"5463","DOI":"10.1002\/cncr.27581","volume":"118","author":"NU Lin","year":"2012","unstructured":"Lin, N. U. et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer 118, 5463\u20135472 (2012).","journal-title":"Cancer"},{"key":"43392_CR2","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E. & Gianni, L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol [Internet]. 13, 674\u2013690 (2016).","journal-title":"Nat Rev Clin Oncol [Internet]."},{"key":"43392_CR3","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann, B. D. et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 121, 2750\u20132767 (2011).","journal-title":"J. Clin. Invest."},{"key":"43392_CR4","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1158\/1078-0432.CCR-10-2560","volume":"17","author":"AM Gonzalez-Angulo","year":"2011","unstructured":"Gonzalez-Angulo, A. M. et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin cancer Res an Off J Am Assoc Cancer Res. 17, 1082\u20131089 (2011).","journal-title":"Clin cancer Res an Off J Am Assoc Cancer Res."},{"key":"43392_CR5","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1093\/annonc\/mdw209","volume":"27","author":"C Winter","year":"2016","unstructured":"Winter, C. et al. Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic. Ann. Oncol. 27, 1532\u20131538 (2016).","journal-title":"Ann. Oncol."},{"key":"43392_CR6","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/j.1349-7006.2004.tb02195.x","volume":"95","author":"K Yoshida","year":"2004","unstructured":"Yoshida, K. & Miki, Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci. 95, 866\u2013871 (2004).","journal-title":"Cancer Sci."},{"key":"43392_CR7","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41586-019-1056-z","volume":"569","author":"F Bertucci","year":"2019","unstructured":"Bertucci, F. et al. Genomic characterization of metastatic breast cancers. Nature 569, 560\u2013564 (2019).","journal-title":"Nature"},{"key":"43392_CR8","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado, R. et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol Off J Eur Soc Med Oncol. 26, 259\u2013271 (2015).","journal-title":"Ann Oncol Off J Eur Soc Med Oncol."},{"key":"43392_CR9","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1200\/JCO.18.01010","volume":"37","author":"S Loi","year":"2019","unstructured":"Loi, S. et al. Tumor-infiltrating lymphocytes and prognosis: A pooled individual patient analysis of early-stage triple-negative breast cancers. J Clin Oncol Off J Am Soc Clin Oncol. 37, 559\u2013569 (2019).","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"key":"43392_CR10","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1093\/jnci\/djab004","volume":"113","author":"LA Emens","year":"2021","unstructured":"Emens, L. A. et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer: Biomarker Evaluation of the IMpassion130 study. J Natl Cancer Inst. 113, 1005\u20131016 (2021).","journal-title":"J Natl Cancer Inst."},{"key":"43392_CR11","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1038\/s43018-020-00139-8","volume":"1","author":"RM Samstein","year":"2021","unstructured":"Samstein, R. M. et al. Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy. Nat cancer. 1, 1188\u20131203 (2021).","journal-title":"Nat cancer."},{"key":"43392_CR12","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nri.2016.58","volume":"16","author":"P Broz","year":"2016","unstructured":"Broz, P. & Dixit, V. M. Inflammasomes: Mechanism of assembly, regulation and signalling. Nat Rev Immunol. 16, 407\u2013420 (2016).","journal-title":"Nat Rev Immunol."},{"key":"43392_CR13","doi-asserted-by":"publisher","first-page":"2000915118","DOI":"10.1073\/pnas.2000915118","volume":"118","author":"IW Tengesdal","year":"2021","unstructured":"Tengesdal, I. W. et al. Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion. Proc Natl Acad Sci [Internet]. 118, 2000915118 (2021).","journal-title":"Proc Natl Acad Sci [Internet]."},{"key":"43392_CR14","doi-asserted-by":"publisher","first-page":"5721","DOI":"10.1158\/0008-5472.CAN-12-0509","volume":"72","author":"MT Chow","year":"2012","unstructured":"Chow, M. T. et al. NLRP3 suppresses NK cell-mediated responses to carcinogen-induced tumors and metastases. Cancer Res. 72, 5721\u20135732 (2012).","journal-title":"Cancer Res."},{"key":"43392_CR15","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","volume":"35","author":"TN Gide","year":"2019","unstructured":"Gide, T. N. et al. Distinct immune cell populations define response to Anti-PD-1 monotherapy and Anti-PD-1\/Anti-CTLA-4 combined therapy. Cancer Cell 35, 238-255.e6 (2019).","journal-title":"Cancer Cell"},{"key":"43392_CR16","doi-asserted-by":"publisher","first-page":"22699","DOI":"10.1073\/pnas.1821218116","volume":"116","author":"SC Wei","year":"2019","unstructured":"Wei, S. C. et al. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. Proc Natl Acad Sci U S A. 116, 22699\u201322709 (2019).","journal-title":"Proc Natl Acad Sci U S A."},{"key":"43392_CR17","doi-asserted-by":"publisher","first-page":"eabq7019","DOI":"10.1126\/scitranslmed.abq7019","volume":"14","author":"B Theivanthiran","year":"2022","unstructured":"Theivanthiran, B. et al. Tumor-intrinsic NLRP3-HSP70-TLR4 axis drives premetastatic niche development and hyperprogression during anti-PD-1 immunotherapy. Sci Transl Med. 14, eabq7019 (2022).","journal-title":"Sci Transl Med."},{"key":"43392_CR18","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1172\/JCI133055","volume":"130","author":"B Theivanthiran","year":"2020","unstructured":"Theivanthiran, B. et al. A tumor-intrinsic PD-L1\/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy. J Clin Invest. 130, 2570\u20132586 (2020).","journal-title":"J Clin Invest."},{"key":"43392_CR19","doi-asserted-by":"publisher","first-page":"17785","DOI":"10.1073\/pnas.2003499117","volume":"117","author":"LJ McLaughlin","year":"2020","unstructured":"McLaughlin, L. J. et al. Pharmacologic induction of innate immune signaling directly drives homologous recombination deficiency. Proc Natl Acad Sci U S A. 117, 17785\u201317795 (2020).","journal-title":"Proc Natl Acad Sci U S A."},{"key":"43392_CR20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2123227119","volume":"119","author":"AA Kogan","year":"2022","unstructured":"Kogan, A. A. et al. Activating STING1-dependent immune signaling in TP53 mutant and wild-type acute myeloid leukemia. Proc Natl Acad Sci U S A. 119, e2123227119 (2022).","journal-title":"Proc Natl Acad Sci U S A."},{"key":"43392_CR21","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.cmpb.2019.05.023","volume":"177","author":"M Og\u0142uszka","year":"2019","unstructured":"Og\u0142uszka, M., Orzechowska, M., J\u0119droszka, D., Witas, P. & Bednarek, A. K. Evaluate cutpoints: Adaptable continuous data distribution system for determining survival in Kaplan-Meier estimator. Comput. Methods Programs Biomed. 177, 133\u2013139 (2019).","journal-title":"Comput. Methods Programs Biomed."},{"key":"43392_CR22","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1084\/jem.20151790","volume":"213","author":"FI Schmidt","year":"2016","unstructured":"Schmidt, F. I. et al. A single domain antibody fragment that recognizes the adaptor ASC defines the role of ASC domains in inflammasome assembly. J Exp Med. 213, 771\u2013790 (2016).","journal-title":"J Exp Med."},{"key":"43392_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","volume":"51","author":"FR Greten","year":"2019","unstructured":"Greten, F. R. & Grivennikov, S. I. Inflammation and cancer: Triggers, mechanisms, and consequences. Immunity 51, 27\u201341. https:\/\/doi.org\/10.1016\/j.immuni.2019.06.025 (2019).","journal-title":"Immunity"},{"key":"43392_CR24","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.cell.2016.03.046","volume":"165","author":"VAK Rathinam","year":"2016","unstructured":"Rathinam, V. A. K. & Fitzgerald, K. A. Inflammasome complexes: Emerging mechanisms and effector functions. Cell 165, 792\u2013800. https:\/\/doi.org\/10.1016\/j.cell.2016.03.046 (2016).","journal-title":"Cell"},{"key":"43392_CR25","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/nature15514","volume":"526","author":"J Shi","year":"2015","unstructured":"Shi, J. et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature 526, 660\u2013665 (2015).","journal-title":"Nature"},{"key":"43392_CR26","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/j.celrep.2018.07.027","volume":"24","author":"M Monteleone","year":"2018","unstructured":"Monteleone, M. et al. Interleukin-1\u03b2 maturation triggers its relocation to the plasma membrane for gasdermin-D-dependent and -independent secretion. Cell Rep [Internet]. 24, 1425\u20131433. https:\/\/doi.org\/10.1016\/j.celrep.2018.07.027 (2018).","journal-title":"Cell Rep [Internet]."},{"key":"43392_CR27","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41586-021-03478-3","volume":"593","author":"S Xia","year":"2021","unstructured":"Xia, S. et al. Gasdermin D pore structure reveals preferential release of mature interleukin-1. Nature 593, 607\u2013611 (2021).","journal-title":"Nature"},{"key":"43392_CR28","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1158\/1078-0432.CCR-18-2202","volume":"25","author":"C Tulotta","year":"2019","unstructured":"Tulotta, C. et al. Endogenous production of IL1B by breast cancer cells drives metastasis and colonization of the bone microenvironment. Clin. Cancer Res. 25, 2769\u20132782 (2019).","journal-title":"Clin. Cancer Res."},{"key":"43392_CR29","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1172\/JCI80005","volume":"125","author":"D Marvel","year":"2015","unstructured":"Marvel, D. & Gabrilovich, D. I. Myeloid-derived suppressor cells in the tumor microenvironment: Expect the unexpected. J. Clin. Invest. 125, 3356\u20133364 (2015).","journal-title":"J. Clin. Invest."},{"key":"43392_CR30","doi-asserted-by":"crossref","unstructured":"Tengesdal IW, Li S, Powers NE, May M, Neff CP, Joosten LAB, et al. Activation of Host-NLRP3 Inflammasome in Myeloid Cells Dictates Response to Anti-PD-1 Therapy in Metastatic Breast Cancers. Pharmaceuticals (Basel). 2022;15.","DOI":"10.3390\/ph15050574"},{"key":"43392_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2022.788437","volume":"9","author":"T Ren","year":"2022","unstructured":"Ren, T., Guo, X., Zhang, J. & Liu, Z. Pyroptosis-related signatures for predicting prognosis in breast cancer. Front Surg. 9, 788437 (2022).","journal-title":"Front Surg."},{"key":"43392_CR32","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1084\/jem.20160392","volume":"214","author":"B Weichand","year":"2017","unstructured":"Weichand, B. et al. S1PR1 on tumor-associated macrophages promotes lymphangiogenesis and metastasis via NLRP3\/IL-1\u03b2. J Exp Med. 214, 2695\u20132713 (2017).","journal-title":"J Exp Med."},{"key":"43392_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202304781","volume":"11","author":"C Pu","year":"2024","unstructured":"Pu, C. et al. Low-dose chemotherapy preferentially shapes the ileal microbiome and augments the response to immune checkpoint blockade by activating AIM2 inflammasome in ileal epithelial cells. Adv. Sci. 11, e2304781 (2024).","journal-title":"Adv. Sci."},{"key":"43392_CR34","doi-asserted-by":"publisher","first-page":"681","DOI":"10.21873\/anticanres.15527","volume":"42","author":"C Song","year":"2022","unstructured":"Song, C., Kendi, A. T., Lowe, V. J. & Lee, S. The A20\/TNFAIP3-CDC20-CASP1 axis promotes inflammation-mediated metastatic disease in triple-negative breast cancer. Anticancer Res. 42, 681\u2013695 (2022).","journal-title":"Anticancer Res."},{"key":"43392_CR35","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.immuni.2015.08.013","volume":"43","author":"J Dupaul-Chicoine","year":"2015","unstructured":"Dupaul-Chicoine, J. et al. The Nlrp3 inflammasome suppresses colorectal cancer metastatic growth in the liver by promoting natural killer cell tumoricidal activity. Immunity 43, 751\u2013763 (2015).","journal-title":"Immunity"},{"key":"43392_CR36","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41416-020-01092-0","volume":"124","author":"C-H Lee","year":"2021","unstructured":"Lee, C.-H. et al. Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma. Br J Cancer. 124, 237\u2013246 (2021).","journal-title":"Br J Cancer."},{"key":"43392_CR37","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1158\/2326-6066.CIR-23-0706","volume":"12","author":"A Menachem","year":"2024","unstructured":"Menachem, A. et al. Unleashing natural IL18 activity using an Anti-IL18BP blocker induces potent immune stimulation and antitumor effects. Cancer Immunol Res. 12, 687\u2013703 (2024).","journal-title":"Cancer Immunol Res."},{"key":"43392_CR38","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","volume":"10","author":"F Martinon","year":"2002","unstructured":"Martinon, F., Burns, K. & Tschopp, J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. 10, 417\u2013426 (2002).","journal-title":"Mol Cell."},{"key":"43392_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/advs.201903616","author":"Q Chen","year":"2020","unstructured":"Chen, Q. et al. BRCA1 deficiency impairs mitophagy and promotes inflammasome activation and mammary tumor metastasis. Adv. Sci. https:\/\/doi.org\/10.1002\/advs.201903616 (2020).","journal-title":"Adv. Sci."},{"key":"43392_CR40","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1158\/0008-5472.CAN-22-1002","volume":"83","author":"A El-Kenawi","year":"2023","unstructured":"El-Kenawi, A. et al. Elevated methionine flux drives pyroptosis evasion in persister cancer cells. Cancer Res. 83, 720\u2013734 (2023).","journal-title":"Cancer Res."},{"key":"43392_CR41","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.159430","author":"AF McLemore","year":"2022","unstructured":"McLemore, A. F. et al. Somatic gene mutations expose cytoplasmic DNA to co-opt the cGAS\/STING\/NLRP3 axis in myelodysplastic syndromes. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.159430 (2022).","journal-title":"JCI Insight"},{"key":"43392_CR42","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1182\/bloodadvances.2020003475","volume":"5","author":"GA Ward","year":"2021","unstructured":"Ward, G. A. et al. Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes. Blood Adv. 5, 2216\u20132228 (2021).","journal-title":"Blood Adv."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43392-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43392-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43392-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T23:42:56Z","timestamp":1779061376000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43392-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,21]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["43392"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-43392-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,21]]},"assertion":[{"value":"22 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Research Ethics Committees of A.C. Camargo Cancer Center (protocol number 2.758.540) and Barretos Cancer Hospital (protocol number 4.617.383) and was conducted in accordance with the Declaration of Helsinki. In accordance with local and national regulations, informed consent to participate was waived due to the retrospective and non-interventional nature of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"15316"}}